What recent performance says about Novavax Novavax (NVAX) has been moving on the radar again, with shares showing a mix of ...

Novavax (NVAX) closed at $9.62 in the latest trading session, marking a -1.23% move from the prior day. The stock exceeded ...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes.

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

A federal judge blocked parts of HHS's vaccine policy changes, siding with medical groups against Robert F. Kennedy Jr.'s ...

Vaccine programmes are being challenged by rising misinformation and an uncertain pipeline for research funding, the World ...

U.S. District Judge Brian Murphy in ‌Boston sided with the American Academy of Pediatrics and other medical groups, which ...

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Immatics today and set a price target of $17.00. Stranahan covers the Healthcare sector, focusing on stocks such as Novavax ...